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ABSTRACT
Objective: Clemastine is widely used as an antihistaminic drug. However, clemastine effectively acts as an antagonist of H1 histamine receptor, it has 
significant burden adverse effects causing common nervous system, psychiatric, and gastrointestinal ailments, as well as rare cardiac and immune 
system disorders. The objective of this study is to investigate whether there is a remarkable impact of clemastine administration on the human 
hormonal pituitary-thyroid-adrenal axis.
Methods: To achieve that, hormonal profile was tested in the sera of males and females treated and untreated individuals with clemastine. This is 
to measure serum estradiol, follicle-stimulating hormone, luteinizing hormone, prolactin, progesterone, dehydroepiandrosterone sulfate, thyroid-
stimulating hormone, triiodothyronine, thyroxine, fasting insulin, and cortisol levels. The circulating hormonal levels were measured quantitatively 
using enzyme-link immunosorbent assay.
Results: We resulted that there were significant differences of the human hormonal profile on clemastine treatment.
Conclusion: Hormonal profiling showed that there were remarkable signatures could be of great interest to underline some recommendations and 
guidelines optimizing the clemastine dosage to avoid burdens associated with the administration of this drug as well as maintain the physiological 
and psychological performances of both sexes exposing to clemastine during the period of allergic treatment.
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INTRODUCTION
The first-generation antihistaminic drug, clemastine, is widely utilized 
for allergic conditions after getting approved. Clemastine was patented 
in 1963 and released commercially with the name “Tavegil®” by sandoz 
in some of European countries including France and Germany, but it is 
currently present in the most of world’s markets [1]. Clemastine is an 
antagonist against H1 histamine receptors and it acts as an inhibitor 
of both vasodilator and vasoconstrictor actions of histamine, and 
constriction of gastrointestinal smooth muscle, which sorts it valuable 
in the management of skin allergies (urticarial, contact dermatitis, 
and itching) and allergic rhinitis (it supports rescue lacrimation, 
rhinorrhea, and sneezing) [2].
There are reported burden side effects of clemastine including 
depression or paradoxical motivation, evidenced by concentration 
problems, drowsiness, dizziness, psychomotor failure, headache, 
fatigue, and aberrant coordination, as well as cholinolytic effects, 
resulting in condensing of bronchial exudations and dry mouth [3].
Other side effects include nausea, insomnia, tachycardia, vertigo, 
vomiting, photophobia, diarrhea or constipation, and obstacles in 
urination among individuals suffering from non-cancerous prostatic 
hyperplasia. If the therapeutic doses of clemastine are not adjusted, this 
may interfere with color vision. Moreover, erythema and allergic rash 
have been indicated [2,4].
Along with the expedient effect of clemastine and others as antihistaminic 
drugs, most medicines can cause unwanted side effects although not 
everyone experiences them. Thus, Tavegil® with clemastine in the form 
of tablets has adverse reactions recorded by health-care professionals 
and world literature including nervous system disorders: Common 
fatigue, common drowsiness, uncommon dizziness, and rare headache, 
and psychiatric disorders: Rare excitability, rare dry mouth, and rare 
gastrointestinal disorders: Rare nausea, very rare constipation, and 
very rare cardiac disorders: Tachycardia and palpitations, rare skin 
rash, and rare immune system aliments: Hypersensitivity conditions 
and dyspnea as well as rare asthenia [2].
The influence of two antihistamine drugs, dexchlorpheniramine, 
and meclastine, on growth hormone (GH) reflection to arginine 
administration and to insulin hypoglycemia in normal volunteers 
was studied previously [5]. Authors found that clemastine analogs 
administration significantly decreased the GH response to arginine 
infusion. These findings propose that histamine is elaborated in the 
regulation of the hormonal release [5].
Another research group [6] observed significant changes in the 
adrenocorticotropic hormone (ACTH) secretion levels on antihistaminic 
drug administration, probably by activation of corticotropin-releasing 
hormone (CRH) or corticotropin-releasing factor (CRF) release.
However, there are many burden side effects were investigated on using 
clemastine, no study reported its effects on human sex and thyroid 
hormonal profiles. Thus, these observations promoted us to investigate, 
as the first time, the drug-hormone interference of the clemastine, 
as an antihistaminic drug for allergic cases, on the pituitary-thyroid-
adrenal axis as follow; (a) sex hormonal profile includes estradiol (E2), 
follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, 
progesterone, dehydroepiandrosterone sulfate (DHEAS), and testosterone, 
(b) thyroid hormonal profile includes thyroid-stimulating hormone (TSH), 
triiodothyronine (T3), and thyroxine (T4), (c) cortisol and fasting insulin.
MATERIALS AND METHODS
Groups
This study has been conducted on 100 adult individuals with ages 
ranging from 30 to 60 years. Volunteers have been divided into two 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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groups; 50 patients group (25 males and 25 females) suffered from 
allergy and 50 healthy controls (25 males and 25 females). Age and 
weight were noticed and determined during the duration of the study. 
Patients and controls had the same average of age and weight.
Treatment protocol
Patients received one (1 mg) tablet twice daily, taken morning and 
evening. Patients only need to take the antihistamine, clemastine, 
for a short while when they have symptoms. Patients stopped 
taking clemastine once symptoms have eased. To exclude other drug 
interactions with clemastine, over-the-counter medicines, vitamins, 
and herbal products, and any medicine other than clemastine were 
avoided during the period of therapy.
Hormonal profiling
Blood samples were drawn via venipuncture from male and female 
allergic patients at the end of the treatment period and healthy controls 
to measure serum FSH, E2, LH, prolactin, progesterone, DHEAS, 
testosterone, TSH, T3, T4, fasting insulin, and cortisol. Blood samples 
were collected from patients, and then all circulating hormonal levels 
were investigated quantitatively using enzyme-linked immunosorbent 
assay kits purchased from DRG International Inc., USA, Diagnostic 
Systems Laboratories Inc., and Adaltis Italia SPA Company, Italy.
Statistical analysis
Data were statistically analyzed using statistical computer program: 
SPSS (Statistical Package for the Social Science; SPSS Inc., version 17.0, 
USA). Data were described in terms of mean and standard errors when 
appropriate. Comparison of variables between the study groups was 
performed using analysis of variance (ANOVA) test. A probability value 
p<0.05 has been considered statistically significant.
RESULTS
Follow-up data gained from all treated patients with clemastine 
antihistaminic drug and healthy persons were figured out. Figs. 1-5 
show the hormonal levels of the pituitary-thyroid-adrenal axis obtained 
from the adult patients received clemastine.
The impact of clemastine on sex hormones
First, the therapeutic impact of clemastine was figured on male and 
female FSH, LH, E2, and prolactin hormonal profile (Fig. 1). Intriguingly, 
there was a significant increase (p<0.05) of male and female E2 among 
treated patients with clemastine compared to healthy control group, 
as illustrated in (Fig. 1). While, there were nonsignificant patterns 
(p>0.05) of FSH, LH, and prolactin when comparing clemastine treated 
patients with untreated controls, as illustrated in (Fig. 1).
Fig. 2 illustrates the antihistaminic effect of clemastine on male and 
female progesterone and testosterone sex hormones. Interestingly, 
there were significant increases (p<0.05) of female progesterone and 
Fig. 1: The therapeutic effect of clemastine on male and female, 
follicle-stimulating hormone, estradiol (E2), luteinizing hormone, 
and prolactin hormonal profile. There is a significant increase (*) 
of male and female E2 when comparing control with patients 
treated with clemastine (p<0.05)
Fig. 2: The antihistaminic effect of clemastine on male and female 
sex hormones. There are significant increases (*) of female 
progesterone and testosterone hormones, male progesterone, 
while a significant decrease of male testosterone when comparing 
control with patients treated with clemastine (p<0.05)
Fig. 3: The antihistaminic effect of clemastine on male and female 
thyroid hormonal axis. There are significant increases (*) of 
female and male thyroid-stimulating hormone, triiodothyronine, 
and thyroxine thyroid hormones when comparing control with 
patients treated with clemastine (p<0.05)
Fig. 4: The therapeutic effect of clemastine on male and 
female fasting insulin and cortisol levels taken in morning and 
evening. There are significant decreases (*) of male and female 
cortisol (morning) and female fasting insulin, while significant 
increases (*) of male and female cortisol (evening) when 
comparing control with patients treated with clemastine (p<0.05)
Fig. 5: The antihistaminic impact of clemastine on male and 
female dehydroepiandrosterone sulfate (DHEAS) levels. There 
is a significant decrease (*) of male DHEAS and a significant 
increase (*) of female DHEAS levels when comparing control with 
patients treated with clemastine (p<0.05)
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testosterone hormones, male progesterone, while a significant decrease 
(p<0.05) of male testosterone when comparing control with patients 
treated with clemastine.
The impact of clemastine on thyroid hormones
The antihistaminic impact of clemastine on male and female thyroid 
hormonal axis (T3, T4, and TSH) was investigated and illustrated in 
(Fig. 3). There were significant increases (p<0.05) of female and male 
TSH and T4 thyroid hormones when comparing control with patients 
treated with clemastine. However, there was a significant increase 
(p<0.05) of male T3 hormone, there was a nonsignificant change 
(p>0.05) of female T3 hormone, when comparing controls with treated 
patients with clemastine, as illustrated in (Fig. 3).
The impact of clemastine on insulin, cortisol, and DHEAS
The therapeutic impact of clemastine on male and female fasting insulin 
and cortisol levels taken in morning and evening was figured out in 
(Fig. 4). Fig. 4 illustrates that there were significant decreases (p<0.05) 
of male and female cortisol (morning) and female fasting insulin, while 
significant increases (p<0.05) of male and female cortisol (evening), 
when comparing control with patients treated with clemastine, as 
shown in (Fig. 4). On the other hand, patients treated with clemastine 
have a nonsignificant change (p>0.05) of male fasting insulin compared 
to healthy untreated controls.
The effect of clemastine on male and female DHEAS levels was figured 
out in Fig. 5. In this figure, there was a significant decrease (p<0.05) 
of male DHEAS and a significant increase (p<0.05) of female DHEAS 
levels when comparing controls with patients treated with clemastine, 
as illustrated in Fig. 5.
DISCUSSION
In this study, we observed that patients treated with clemastine drug 
have revealed significant elevations in thyroid hormones (TSH, T3, and 
T4) compared to healthy controls, which can result in severe impairment 
in thyroid axis and disturbance in the functional homeostasis of the body 
paralleled by burden adverse events. These drug-thyroid interference 
observations are in agreement with some previous studies indicated 
that nitrofurantoin and flavoxate hydrochloride drugs [7], spasmo 
canulase and librax drugs [8], and Allopurinol drug [9] may affect 
the human thyroid hormones (TSH, T3, and T4), in addition to other 
drugs alter TSH [10], and thyrotropin-releasing hormone receptor [11]. 
Therefore, it seems to go in parallel with the noteworthy elevations of 
the thyroid hormones in patients subjected to clemastine.
Intriguingly, we found also that clemastine administration affects 
males and females sex hormonal profile (E2, DHEAS, progesterone, 
and testosterone), which may affect negatively on the human fertility 
and sexuality. These results came in agreement of our previous 
observations [7-9].
Histamine antagonists utilized to relieve allergic conditions are 
ubiquitous drugs infused annually in thousands of patients around the 
world. With this wide usage of a drug, exceptionally slight detrimental 
effects are manifested. The estimation of these side effects is the focus 
of the most of the researchers. According to the summary of clemastine 
characteristics [12], the most common (>1/100, <1/10) side effects 
are: Fatigue and drowsiness. Dizziness is uncommon (>1/1,000, 
<1/100), while nausea-related headache, hypersensitivity conditions, 
excitability, dyspnea, dry mouth, skin rash, and asthenia fit to rare 
unwanted impacts of clemastine (>1/10,000, <1/1,000). The recorded 
very rare insults (<1/10,000) include tachycardia, palpitations, and 
constipation.
Due to these lack of studies indicating the impact of antihistaminic drugs 
on sex and thyroid hormonal release profiles, we decided to investigate 
the clemastine effect on human pituitary-thyroid-adrenal axis, including 
E2, FSH, LH, progesterone, prolactin, DHEAS, testosterone, T3, T3, TSH, 
cortisol, and fasting insulin.
In a mechanistic point of view, it was found that because of the existence 
of histamine in most of the tissues including central nervous system 
(CNS) with particularly hypothalamus and the median eminence, 
it may control hormonal secretion levels [5]. Therefore, blocking 
histamine using antihistaminic drugs may alter the hormonal secretion 
homeostasis [5], which in turn supports our findings. Pontiroli et al. [5] 
studied the influence of two antihistamine drugs, dexchlorpheniramine, 
and meclastine, on the GH reflection to arginine administration and 
to insulin hypoglycemia in 30 healthy controls. They found that their 
administration meaningfully suppressed the GH response to arginine 
administration, but neither drug affected the release of GH following 
insulin hypoglycemia. These data augment that histamine is enrolled in 
controlling of hormones secretion.
Allolio and his companions [6] studied the effect of the antihistaminic, 
Meclastine, on ACTH response to insulin hypoglycemia and to 
metyrapone-based hypocortisolemia in healthy persons. They reported 
that meclastine administration retracted the hypoglycemia-induced 
ACTH and cortisol elevation while serum GH and prolactin levels were 
unchanged. Our outcomes provision the idea of an excitatory effect 
of histamine on ACTH release throughout H1 receptors, probably by 
stimulation of CRF or what so called CRH release.
Our data are consistent with the finding that antihistaminic drugs 
control hormones release and with the previous data evidencing that 
the release of hormones in response to altered stimuli is subjected to 
various regulatory pathways [13].
The main serious adverse events are drowsiness, weakened matching, 
improvement of the CNS depressant action of other associated drugs 
and a cholinolytic effect. Woroñ and his companions [14,15] suggested 
that prescribers must be extremely cautious when administering several 
antihistamines to be taken concurrently by one patient. When choosing 
drugs, the risk of drug interactions should be taken in consideration 
so as to avoid an enlarged risk of thoughtful adverse feedbacks. The 
recorded symptoms of the side effect should thus be started as a cross-
drug interface including the collective depressive impact of supposed 
drugs on the CNS.
Only one adverse response report versus an estimate of over 
3 million treatments may, however, propose the low sensitivity of 
this pharmacovigilance scheme. This may consequence from a weak 
of awareness between medical specialists on the practicality of any 
adverse drug-based statistics, involving known and common adverse 
events.
The electronic drug safety RISK catalog [16] involving consumer data 
contains over 200 sheets where clemastine was the doubtful drug 
covering over 100 responses, of which 165 do not stipulate the patient’s 
country. The database contained over 3 million sheets acquiesced to the 
food and drug administration’s from the first of January 2004 to the end 
of March 2012, of which a 3rd originate from outdoor the United States 
of America. These contain over 5 million drugs alleged of producing 
over 14 million side impacts, so clemastine-related reports contain 
0.005% of all the reports.
The effect of clemastine on the stimulation of itch by prostaglandin 
E1 (PGE1) was investigated by Boss’s group in normal subjects [17]. 
The antihistamine drug did not eliminate the potentiation, which 
proposes that the PGE1 impact on itch does not related to the release of 
endogenous histamine.
Liu et al. [18] found that clemastine promotes higher values of repressive 
histone methylation (H3K9me3), a marker for heterochromatin, in 
oligodendrocytes, but not neurons, of the PFC. This was reliable with 
the competence of clemastine in enhancing the activity of the H3K9 
histonemethyltransferases in oligodendrocytes originated from 
primary culture, an consequence that could be reversed by cotherapy 
with muscarine. Scientists’ findings augment that endorsing adult 
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myelination is a potent approach for retrogressive depressive-based 
social performance.
Due to the worldwide ongoing interest in the drug design and 
formulation with potential applications in health and drug delivery for 
disease [19], some polymers were generally used such as Carbopol 934P 
and Carbopol 940P [20], polysorbate 80 [21], and poly D-L-lactide-
co-glycolide [22], providing unique physicochemical characteristics. 
On the basis of drug design, desloratadine, a histamine H1 receptor 
antagonist, was formulated using polymers such as Carbopol 934P 
and Carbopol 940P. Authors found that the stability of this formula is 
greater than the free counterpart and the calculated shelf life data were 
found to be more than 2 years [20]. Moreover, bepotastine besilate, a 
recent second-generation antihistamine, was developed and validated 
for stability in quality control laboratories [19].
CONCLUSION
These sex and thyroid hormonal profiles could be of great interest 
in drug-dosage optimization. Its alteration may lead to malfunction 
in the physiological performance of both sexes associated with bad 
psychological effects. Dosage optimization depending on drug-hormone 
interference effect is an important key element must be taken into 
consideration in the treatment of allergic conditions using clemastine, 
helping us to avoid the burden side effects on sexuality and thyroid 
functions that may be occurred in reflect to inaccurate clemastine dose 
administration. Providing new drug formulations for controlled release 
with high stability is warranted for further studies to tackle these 
burden side effects.
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